Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 232 Pages Transparency Market Research Pvt. Ltd. April, 2024 TNPR18827805
Best Price Guarantee
Price from $5,795
Length 232 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date April, 2024
SKU TNPR18827805

Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Companion Diagnostic Tests in Oncology Market – Scope of Report

TMR’s report on the global companion diagnostic tests in oncology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global companion diagnostic tests in oncology market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global companion diagnostic tests in oncology market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the companion diagnostic tests in oncology market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global companion diagnostic tests in oncology market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global companion diagnostic tests in oncology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global companion diagnostic tests in oncology market.

The report delves into the competitive landscape of the global companion diagnostic tests in oncology market. Key players operating in the global companion diagnostic tests in oncology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global companion diagnostic tests in oncology market profiled in this report.

Key Questions Answered in Global companion diagnostic tests in oncology Market Report
  • What is the sales/revenue generated by companion diagnostic tests in oncology across all regions during the forecast period?
  • What are the opportunities in the global companion diagnostic tests in oncology market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Companion Diagnostic Tests in Oncology Market – Research Objectives and Research Approach

The comprehensive report on the global companion diagnostic tests in oncology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global companion diagnostic tests in oncology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global companion diagnostic tests in oncology market.


1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
        6.3.1. Protein Detection
6.3.1.1. Immunohistochemistry
        6.3.2. DNA Detection
6.3.2.1. Polymerase Chain Reaction (PCR)
6.3.2.2. Next-generation Sequencing (NGS)
6.3.2.3. In Situ Hybridization
        6.3.3. Others
    6.4. Market Attractiveness, by Detection Technique
7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Biomarker, 2020 - 2034
        7.3.1. EGFR
        7.3.2. KRAS
        7.3.3. HER2
        7.3.4. BRAF V600E
        7.3.5. Others
        7.3.6. 7.4 Market Attractiveness, by Biomarker
8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
        8.3.1. Breast Cancer
        8.3.2. Lung Cancer
        8.3.3. Colorectal Cancer
        8.3.4. Liver Cancer
        8.3.5. Melanoma
        8.3.6. Others
    8.4. Market Attractiveness, by Cancer Type
9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2020 - 2034
        9.3.1. Hospitals
        9.3.2. Specialty Clinics
        9.3.3. Diagnostic Labs
        9.3.4. Others
    9.4. Market Attractiveness, by End-user
10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2020 - 2034
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region
11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
        11.2.1. Protein Detection
11.2.1.1. Immunohistochemistry
        11.2.2. DNA Detection
11.2.2.1. Polymerase Chain Reaction (PCR)
11.2.2.2. Next-generation Sequencing (NGS)
11.2.2.3. In Situ Hybridization
        11.2.3. Others
    11.3. Market Attractiveness, by Detection Technique
    11.4. Market Value Forecast, by Biomarker, 2020 - 2034
        11.4.1. EGFR
        11.4.2. KRAS
        11.4.3. HER2
        11.4.4. BRAF V600E
        11.4.5. Others
    11.5. Market Attractiveness, by Biomarker
    11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
        11.6.1. Breast Cancer
        11.6.2. Lung Cancer
        11.6.3. Colorectal Cancer
        11.6.4. Liver Cancer
        11.6.5. Melanoma
        11.6.6. Others
    11.7. Market Attractiveness, by Cancer Type
    11.8. Market Value Forecast, by End-user, 2020 - 2034
        11.8.1. Hospitals
        11.8.2. Specialty Clinics
        11.8.3. Diagnostic Labs
        11.8.4. Others
    11.9. Market Attractiveness, by End-user
    11.10. Market Value Forecast, by Country, 2020 - 2034
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Detection Technique
        11.11.2. By Biomarker
        11.11.3. By Cancer Type
        11.11.4. By End-user
        11.11.5. By Country
12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
        12.2.1. Protein Detection
12.2.1.1. Immunohistochemistry
        12.2.2. DNA Detection
12.2.2.1. Polymerase Chain Reaction (PCR)
12.2.2.2. Next-generation Sequencing (NGS)
12.2.2.3. In Situ Hybridization
        12.2.3. Others
    12.3. Market Attractiveness, by Detection Technique
    12.4. Market Value Forecast, by Biomarker, 2020 - 2034
        12.4.1. EGFR
        12.4.2. KRAS
        12.4.3. HER2
        12.4.4. BRAF V600E
        12.4.5. Others
    12.5. Market Attractiveness, by Biomarker
    12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
        12.6.1. Breast Cancer
        12.6.2. Lung Cancer
        12.6.3. Colorectal Cancer
        12.6.4. Liver Cancer
        12.6.5. Melanoma
        12.6.6. Others
    12.7. Market Attractiveness, by Cancer Type
    12.8. Market Value Forecast, by End-user, 2020 - 2034
        12.8.1. Hospitals
        12.8.2. Specialty Clinics
        12.8.3. Diagnostic Labs
        12.8.4. Others
    12.9. Market Attractiveness, by End-user
    12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Detection Technique
        12.11.2. By Biomarker
        12.11.3. By Cancer Type
        12.11.4. By End-user
        12.11.5. By Country/Sub-region
13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
        13.2.1. Protein Detection
13.2.1.1. Immunohistochemistry
        13.2.2. DNA Detection
13.2.2.1. Polymerase Chain Reaction (PCR)
13.2.2.2. Next-generation Sequencing (NGS)
13.2.2.3. In Situ Hybridization
        13.2.3. Others
    13.3. Market Attractiveness, by Detection Technique
    13.4. Market Value Forecast, by Biomarker, 2020 - 2034
        13.4.1. EGFR
        13.4.2. KRAS
        13.4.3. HER2
        13.4.4. BRAF V600E
        13.4.5. Others
    13.5. Market Attractiveness, by Biomarker
    13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
        13.6.1. Breast Cancer
        13.6.2. Lung Cancer
        13.6.3. Colorectal Cancer
        13.6.4. Liver Cancer
        13.6.5. Melanoma
        13.6.6. Others
    13.7. Market Attractiveness, by Cancer Type
    13.8. Market Value Forecast, by End-user, 2020 - 2034
        13.8.1. Hospitals
        13.8.2. Specialty Clinics
        13.8.3. Diagnostic Labs
        13.8.4. Others
    13.9. Market Attractiveness, by End-user
    13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Detection Technique
        13.11.2. By Biomarker
        13.11.3. By Cancer Type
        13.11.4. By End-user
        13.11.5. By Country/Sub-region
14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
        14.2.1. Protein Detection
14.2.1.1. Immunohistochemistry
        14.2.2. DNA Detection
14.2.2.1. Polymerase Chain Reaction (PCR)
14.2.2.2. Next-generation Sequencing (NGS)
14.2.2.3. In Situ Hybridization
        14.2.3. Others
    14.3. Market Attractiveness, by Detection Technique
    14.4. Market Value Forecast, by Biomarker, 2020 - 2034
        14.4.1. EGFR
        14.4.2. KRAS
        14.4.3. HER2
        14.4.4. BRAF V600E
        14.4.5. Others
    14.5. Market Attractiveness, by Biomarker
    14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
        14.6.1. Breast Cancer
        14.6.2. Lung Cancer
        14.6.3. Colorectal Cancer
        14.6.4. Liver Cancer
        14.6.5. Melanoma
        14.6.6. Others
    14.7. Market Attractiveness, by Cancer Type
    14.8. Market Value Forecast, by End-user, 2020 - 2034
        14.8.1. Hospitals
        14.8.2. Specialty Clinics
        14.8.3. Diagnostic Labs
        14.8.4. Others
    14.9. Market Attractiveness, by End-user
    14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Detection Technique
        14.11.2. By Biomarker
        14.11.3. By Cancer Type
        14.11.4. By End-user
        14.11.5. By Country/Sub-region
15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
        15.2.1. Protein Detection
15.2.1.1. Immunohistochemistry
        15.2.2. DNA Detection
15.2.2.1. Polymerase Chain Reaction (PCR)
15.2.2.2. Next-generation Sequencing (NGS)
15.2.2.3. In Situ Hybridization
        15.2.3. Others
    15.3. Market Attractiveness, by Detection Technique
    15.4. Market Value Forecast, by Biomarker, 2020 - 2034
        15.4.1. EGFR
        15.4.2. KRAS
        15.4.3. HER2
        15.4.4. BRAF V600E
        15.4.5. Others
    15.5. Market Attractiveness, by Biomarker
    15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
        15.6.1. Breast Cancer
        15.6.2. Lung Cancer
        15.6.3. Colorectal Cancer
        15.6.4. Liver Cancer
        15.6.5. Melanoma
        15.6.6. Others
    15.7. Market Attractiveness, by Cancer Type
    15.8. Market Value Forecast, by End-user, 2020 - 2034
        15.8.1. Hospitals
        15.8.2. Specialty Clinics
        15.8.3. Diagnostic Labs
        15.8.4. Others
    15.9. Market Attractiveness, by End-user
    15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Detection Technique
        15.11.2. By Biomarker
        15.11.3. By Cancer Type
        15.11.4. By End-user
        15.11.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2023)
    16.3. Company Profiles
        16.3.1. Abbott
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
        16.3.2. F. Hoffmann-LA Roche AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
        16.3.3. Genomic Health, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
        16.3.4. QIAGEN
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
        16.3.5. Agilent Technologies, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
        16.3.6. AGENDIA N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
        16.3.7. bioMérieux SA
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
        16.3.8. Illumina, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
        16.3.9. Siemens Healthineers
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
        16.3.10. Thermo Fisher Scientific Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
        16.3.11. BioGenex
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings